The purpose of this protocol is to provide continued treatment access and safety follow-up
for eligible participants who continue to derive a benefit from study intervention in the
Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety
data collection will permit further characterization of the safety profile of lorlatinib in
participants continuing to receive study intervention